As of 2025-10-19, the Intrinsic Value of Relmada Therapeutics Inc (RLMD) is -10.26 USD. This RLMD valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.01 USD, the upside of Relmada Therapeutics Inc is -610.28%.
Based on its market price of 2.01 USD and our intrinsic valuation, Relmada Therapeutics Inc (RLMD) is overvalued by 610.28%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -10.26 - -10.26 | -10.26 | -610.28% |
| P/E | (33.89) - (38.48) | (34.87) | -1834.9% |
| DDM - Stable | (17.96) - (56.38) | (37.17) | -1949.2% |
| DDM - Multi | (19.36) - (47.78) | (27.62) | -1474.1% |
| Market Cap (mil) | 66.71 |
| Beta | 1.62 |
| Outstanding shares (mil) | 33.19 |
| Enterprise Value (mil) | 66.71 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.63% |
| Cost of Debt | 5.00% |
| WACC | 6.65% |